Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
3.78 M
Value Traded
58.14 M
Short % Float
-
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
-
EPS (TTM)
-
P/E Ratio
-
Ent. Value
-
Total Shares
-
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VVVV Catalyst Timeline
Dated clinical, regulatory and corporate events for vVARDIS Holding AG
Past FDA Catalysts and PDUFA Decisions
How VVVV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
vVARDIS Holding AG is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every VVVV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| No insider trades match the selected filters. | |||||
Hedge Fund 13F Activity
Hedge Funds invested in VVVV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VVVV for Q2 2026. | ||||
Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VVVV ranks across every disease it competes in
Competitive Position is a premium feature
See how VVVV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVVVV News
-VVVV
Nov 13, 2026The NYSE Welcomes vVARDIS as a Publicly Listed Company
vVARDIS, co-founded by Dr. Haley and Dr. Goly Abivardi, has launched as a publicly listed company on the NYSE. The Swiss dental technology firm aims to transform dental care with its innovative product, Curodont® Repair Fluoride Plus, which treats early tooth decay without drills or needles. This approach addresses a significant global health issue, as billions suffer from untreated cavities.
Read more →-VVVV
Nov 13, 2026vVARDIS Announces Pricing of Initial Public Offering
vVARDIS Holding AG priced its IPO at $18 per share for 9,722,223 Class A ordinary shares. The Swiss dental med-tech firm granted underwriters a 30-day option to buy 1,458,333 more shares. This offering marks the company's entry into the public markets.
Read more →About vVARDIS Holding AG
BIOPHARMAWATCH ELITE
Trade the next VVVV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime